LUND, Sweden, Sept. 24, 2025 — Hansa Biopharma has announced that imlifidase successfully met its primary endpoint in the pivotal US Phase 3 ConfIdeS trial for kidney transplantation in highly sensitized patients. At 12 months, patients treated with imlifidase achieved a mean eGFR of 51.5 mL/min/1.73m² compared to 19.3 mL/min/1.73m² in the control arm, representing a statistically significant improvement. The therapy was generally well tolerated, and the company plans to submit a Biologic License Application (BLA) to the US FDA by the end of 2025 under the accelerated approval pathway.
Science Significance
The ConfIdeS trial marks a major breakthrough in desensitization therapy for kidney transplantation, an area with limited innovation in the past three decades. By effectively cleaving IgG antibodies and preventing rejection, imlifidase enables transplantation for highly sensitized patients who would otherwise face years on dialysis or limited compatibility options.
Regulatory Significance
The planned BLA submission to the FDA under accelerated approval highlights imlifidase’s potential as a first-in-class therapy. With robust Phase 3 data and previous conditional approvals in Europe, the US filing could represent a paradigm shift in regulatory acceptance of innovative desensitization strategies for organ transplantation.
Business Significance
Advertisement
Successful Phase 3 outcomes significantly enhance the commercial prospects for imlifidase. The therapy already has approvals in Europe, the UK, Australia, and Switzerland, and US entry would position it as a global standard in transplant desensitization. Positive results also strengthen investor confidence in Hansa Biopharma’s clinical pipeline and IgG-cleaving technology platform.
Patients’ Significance
For highly sensitized kidney transplant patients, who often face years of dialysis or organ rejection, imlifidase offers new hope for successful transplants and improved long-term survival. The therapy directly addresses one of the most underserved patient populations in nephrology and transplantation.
Policy Significance
The results highlight the need for healthcare systems and policy frameworks to support rapid adoption of breakthrough therapies in transplantation. With 170,000 patients awaiting kidney transplants across the US and Europe, broader access to desensitization treatments could ease the burden on dialysis systems and improve health outcomes globally.
The Phase 3 success of imlifidase in the ConfIdeS trial marks a landmark achievement in transplantation medicine. By combining clinical efficacy, regulatory momentum, and patient-centered benefits, this development brings the promise of expanded access to kidney transplants for highly sensitized patients and strengthens the future role of antibody-cleaving therapies in modern healthcare.
Source: Hansa Biopharma Press Release
